These mutations are linked to increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs), making EGFR TKIs a primary treatment option for non-small cell lung cancer (NSCLC) patients [2–4]. Here, EGFR is linked to non-small cell lung carcinoma.